This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Clinical Outsourcing Remove Pharma Companies Remove Research Related Topics
Reagent DNA Licensing Clinical Development Protein Development Regulation Drugs Vaccine Vaccination More Related Topics >
article thumbnail

Private equity firms play ‘pass the Parexel’ with $8.5bn handover deal

pharmaphorum

JULY 5, 2021

billion to claim ownership of the contract research organisation. The handover comes four years after Pamplona Capital Management bought the company for around $5 billion, and just a few weeks after lab tech company Thermo Fisher Scientific agreed to acquire another CRO – PPD – in a deal valued at $17.4

Clinical Trials 64
Clinical Trials Clinical Trials Regulation Trials 64
article thumbnail

Listicle: Maximising outsourcing models beyond time and cost

Drug Discovery World

SEPTEMBER 29, 2022

For these reasons and others, many biotech and pharmaceutical companies – along with government research labs and academic institutions – rely on contract research organizations (CROs) for drug discovery services. Big pharma companies routinely maintain their own decks of upwards of millions of compounds.

Reagent 52
Reagent DNA Scientist Drugs 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024